This inventor holds 10 USPTO granted patents. Top assignees: The United States of America as Represented by the Department of Health, The United States of America as Represented by the Secretary of, University of Illinois. Active years: 1995-2004.
Company Filing History:
5 out of 1,217 
3 out of 2,202 
2 out of 2,420 
Years Active: 1995-2004
Title: Gordon M Cragg: Innovator in Antiviral Compounds
Introduction
Gordon M Cragg is a notable inventor based in Bethesda, MD (US). He has made significant contributions to the field of antiviral compounds, holding a total of 10 patents. His work has focused on developing novel compounds that can inhibit the growth of viruses, particularly those related to human immunodeficiency virus (HIV).
Latest Patents
One of Cragg's latest patents is titled "Calanolide and related antiviral compounds, compositions, and uses thereof." This invention provides novel antiviral compounds known as calanolides, which can be isolated from plants of the genus Calophyllum. These compounds and their derivatives may be utilized alone or in combination with other antiviral agents in pharmaceutical compositions to inhibit the replication of retroviruses, specifically HIV-1 and HIV-2.
Career Highlights
Throughout his career, Gordon M Cragg has worked with esteemed organizations, including the United States of America as represented by the Department of Health. His research has significantly advanced the understanding and treatment of viral infections.
Collaborations
Cragg has collaborated with notable colleagues such as Michael R Boyd and James Brislin McMahon, contributing to the development of innovative antiviral solutions.
Conclusion
Gordon M Cragg's work in the field of antiviral compounds has made a lasting impact on medical research and treatment options for viral infections. His innovative contributions continue to inspire advancements in pharmaceutical sciences.